1077 related articles for article (PubMed ID: 30354852)
41. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
Kurosawa M; Sutoh E
J Investig Allergol Clin Immunol; 2019; 29(1):40-45. PubMed ID: 29957591
[TBL] [Abstract][Full Text] [Related]
42. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
43. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
44. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
45. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
46. Benralizumab for the treatment of asthma.
Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
[TBL] [Abstract][Full Text] [Related]
47. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
48. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
49. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
51. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
52. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
53. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
[TBL] [Abstract][Full Text] [Related]
54. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
Ramonell RP; Iftikhar IH
Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
[TBL] [Abstract][Full Text] [Related]
55. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
56. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
57. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
58. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
59. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
[No Abstract] [Full Text] [Related]
60. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]